Abstract
Background: As a metabolic and lifestyle disorder, diabetes mellitus poses a prodigious health risk. Out of the many key targets, DPP-IV is one of the very imperative therapeutic targets for the treatment of diabetic patients.
Methods: In our current study, we have done the in silico simulations of ADME-T properties for naturally originated potent DPP-IV inhibitors like quinovic acid, stigmasterol, quinovic acid-3-beta-D-glycopyranoside, zygophyloside E, and lupeol. Structural topographies associated with different pharmacokinetic properties have been systematically assessed.
Results: Glycosylation on quinovic acid is found to be noteworthy for the improvement of pharmacokinetic and toxicological properties, which leads to the prediction that zygophyloside E can be further tailored down to get the lead DPP-IV inhibitor.
Conclusion: This assessment provides useful insight into the future development of novel drugs for the treatment of diabetes mellitus.
Keywords: Dipeptidyl peptidase 4, diabetes mellitus, pharmacokinetic predictions, antidiabetic agents, systematic assessment, glycosylation.
Graphical Abstract
[http://dx.doi.org/10.4103/0973-1296.172956] [PMID: 27013789]
[http://dx.doi.org/10.7150/jca.35607] [PMID: 31942181]
[http://dx.doi.org/10.2174/1381612823666170823103830] [PMID: 28831925]
[http://dx.doi.org/10.3389/fendo.2019.00389] [PMID: 31275246]
[http://dx.doi.org/10.2174/1389203720666190502154129] [PMID: 31057098]
[PMID: 20975810]
[http://dx.doi.org/10.2174/1568026619666191025154834] [PMID: 31654510]
[http://dx.doi.org/10.1016/j.jep.2014.08.017] [PMID: 25169215]
[http://dx.doi.org/10.1111/j.1463-1326.2007.00705.x] [PMID: 17300591]
[http://dx.doi.org/10.1007/s00044-014-1227-2]
[http://dx.doi.org/10.1021/ci6003515] [PMID: 17381169]
[http://dx.doi.org/10.2174/1871530319666181128100206] [PMID: 30484412]
[http://dx.doi.org/10.2174/1568026619666181224111319] [PMID: 30582479]
[http://dx.doi.org/10.2174/1570159X14666161229115508] [PMID: 28034283]
[http://dx.doi.org/10.1021/ci900406x] [PMID: 20433177]
[http://dx.doi.org/10.1016/j.drudis.2013.02.008] [PMID: 23458995]
[http://dx.doi.org/10.1093/nar/gky318] [PMID: 29718510]
[http://dx.doi.org/10.1016/j.jep.2016.01.036] [PMID: 26821190]
[PMID: 22256756]
[http://dx.doi.org/10.1016/j.steroids.2020.108584] [PMID: 31982421]
[http://dx.doi.org/10.1038/s41598-019-57188-y] [PMID: 31941962]
[http://dx.doi.org/10.3389/fpls.2019.01599] [PMID: 31921248]
[http://dx.doi.org/10.1016/j.jsps.2019.11.001] [PMID: 31920428]
[http://dx.doi.org/10.1186/s12906-019-2776-1] [PMID: 31829185]
[http://dx.doi.org/10.1038/s42003-018-0245-x] [PMID: 30675518]
[http://dx.doi.org/10.1002/jssc.201600589] [PMID: 27591043]
[http://dx.doi.org/10.1080/14786419.2015.1118630] [PMID: 26795069]
[http://dx.doi.org/10.1080/14786419.2020.1715397] [PMID: 31971020]
[http://dx.doi.org/10.1177/1177932219896538] [PMID: 31903022]
[PMID: 31867630]
[http://dx.doi.org/10.1080/14786419.2019.1700252] [PMID: 31815547]
[PMID: 31792765]
[http://dx.doi.org/10.1007/s13197-019-03909-0] [PMID: 31686694]
[http://dx.doi.org/10.4103/0973-1296.172960] [PMID: 27013793]
[PMID: 24310212]
[http://dx.doi.org/10.1159/000430353] [PMID: 26303164]
[http://dx.doi.org/10.3748/wjg.v19.i15.2298] [PMID: 23613622]
[http://dx.doi.org/10.1007/s00592-020-01479-8] [PMID: 31955260]
[http://dx.doi.org/10.1002/dmrr.3004] [PMID: 29573125]
[http://dx.doi.org/10.1038/s41598-017-07921-2] [PMID: 28811622]
[http://dx.doi.org/10.1016/j.pharmthera.2020.107503] [PMID: 32061923]